Boston Scientific Corp (BSX) (Q3 2026) Earnings Call Highlights: Cyber Incident Slashes
Boston Scientific (BSX) reported Q3 2026 earnings below expectations due to a cyber incident, with organic sales growth of 1.5% and adjusted EPS of $0.73. The company expects continued pressure in 2027 but anticipates growth from new product launches and market expansions. BSX plans $500M in savings from restructuring and expects to close the Penumbra acquisition in early 2027.
How this was made
The 30-second read
Why it matters
The disclosed cyber incident impacts both revenue growth and EPS, with an explicit carryover into Q4. Management also sets a conservative 2027 framework with continued WATCHMAN and EP pressure, while pointing to 2028 growth catalysts (ICE and Farapulse Ultra) and restructuring savings.
Market read
Traders can update near-term expectations for BSX’s revenue/EPS trajectory based on the quantified cyber incident drag and the conservative 2027 outlook, while monitoring the timing of 2027-2028 launches for the next inflection.
What to watch
The article notes forecasting process enhancements and that some Q4 impact is tied to customer stocking burn-off, which could mean the worst of the disruption is front-loaded rather than persistent.
Background
The piece summarizes Boston Scientific’s Q3 2026 earnings call, emphasizing a cybersecurity incident that disrupted sales growth and forecasting, alongside restructuring and a multi-year product roadmap.
Ticker impact
Boston Scientific guided Q3 organic sales growth to 1.5% below range due to a cybersecurity incident, cutting EPS by $0.07 and adding 200-300 bps headwind into Q4.
Likely near-term pressure as investors price the disclosed Q3 miss, the ongoing Q4 headwind, and the conservative 2027 outlook.
The article provides specific quantified impacts (300 bps Q3 revenue headwind, $0.07 EPS hit, and 200-300 bps ongoing Q4 impact) plus a 2027 framework that assumes continued WATCHMAN/EP pressure until later launches.
Market effects
Medical device peers may face read-across on how operational disruptions (cybersecurity) can temporarily impair procedure demand and forecasting accuracy.
US-focused interventional cardiology demand signals may weigh on sentiment for US procedure-linked medtech names.
China pricing pressure and delayed competitive dynamics highlighted by BSX can influence broader medtech margin expectations.
Counterpoint
The restructuring savings ($500M+ over three years) and the staged 2027-2029 product cadence could outweigh the temporary cyber disruption, making the selloff more about timing than underlying demand.
Key entities
- companyBoston Scientific Corp
BSX, interventional cardiology and medtech company reporting Q3 2026 call highlights including cybersecurity incident impacts, restructuring savings, and 2027-2029 product roadmap.
- executiveJonathan Monson
CFO cited quantified cyber incident headwinds and restructuring savings delivery timing.
- executiveMichael Mahoney
CEO provided the conservative 2027 framework and 2028 growth expectations tied to product launches and market dynamics.
